Proteome Sciences released its earnings results on Aug 04, 2022. The company reported 0p earnings per share for the quarter, the consensus estimate of N/A by 0p.

Q: Is Proteome Sciences overvalued?

According to Wall Street analysts Proteome Sciences’s price is currently Overvalued. Get more investment ideas with TipRanks Premium

Q: Does Proteome Sciences pay dividends?

Proteome Sciences does not currently pay dividends.

Q: What is Proteome Sciences’s EPS estimate?

Proteome Sciences’s EPS estimate for its next earnings report is not yet available.

Q: How many shares outstanding does Proteome Sciences have?

Proteome Sciences has 295,182,040 shares outstanding.

Q: What happened to Proteome Sciences’s price movement after its last earnings report?

Proteome Sciences reported an EPS of 0p in its last earnings report, expectations of N/A. Following the earnings report the stock price went up 0.775%.

Q: Which hedge fund is a major shareholder of Proteome Sciences?

Currently, no hedge funds are holding shares in GB:PRM

1 Followers

PRM Stock Chart & Stats

Advanced Chart >

Day’s Range0p - 0p

52-Week Range3.15p - 5.05p

Previous Close3.9p

Volume26.36K

Average Volume (3M)198.02K

Market CapN/A

Enterprise ValueN/A

Total Cash (Recent Filing)N/A

Total Debt (Recent Filing)N/A

Price to Earnings (P/E)22.5

Beta0.32

Next EarningsMar 30, 2023

EPS EstimateN/A

Next Dividend Ex-DateN/A

Dividend YieldN/A

1Y Price TargetN/A

EPS (TTM)<0.01

Shares Outstanding295,182,056

R-Squared0.00077

Standard Deviation0.16

10 Day Avg. Volume348,155

30 Day Avg. Volume198,024

Price to Book (P/B)-1.75

Price to Sales (P/S)3.50

Price to Cash Flow (P/CF)7.00

P/FCF Ratio12.30

Enterprise Value/RevenueN/A

Enterprise Value/Gross ProfitN/A

Enterprise Value/EbitdaN/A

Price Target UpsideN/A

Rating ConsensusN/A

Alpha-0.01

Number of Analyst Covering0

PRM FAQ

What was Proteome Sciences’s price range in the past 12 months?

Proteome Sciences lowest stock price was 3.15p and its highest was 5.05p in the past 12 months.

What is Proteome Sciences’s market cap?

Currently, no data Available

When is Proteome Sciences’s upcoming earnings report date?

Proteome Sciences’s upcoming earnings report date is Mar 30, 2023 which is in 59 days.

How were Proteome Sciences’s earnings last quarter?

Proteome Sciences released its earnings results on Aug 04, 2022. The company reported 0p earnings per share for the quarter, the consensus estimate of N/A by 0p.

Is Proteome Sciences overvalued?

According to Wall Street analysts Proteome Sciences’s price is currently Overvalued. Get more investment ideas with TipRanks Premium

Does Proteome Sciences pay dividends?

Proteome Sciences does not currently pay dividends.

What is Proteome Sciences’s EPS estimate?

Proteome Sciences’s EPS estimate for its next earnings report is not yet available.

How many shares outstanding does Proteome Sciences have?

Proteome Sciences has 295,182,040 shares outstanding.

What happened to Proteome Sciences’s price movement after its last earnings report?

Proteome Sciences reported an EPS of 0p in its last earnings report, expectations of N/A. Following the earnings report the stock price went up 0.775%.

Which hedge fund is a major shareholder of Proteome Sciences?

Currently, no hedge funds are holding shares in GB:PRM

---

Proteome Sciences Stock Smart Score

Not Ranked

Technicals

SMA

Negative

20 days / 200 days

Momentum

-14.28%

12-Months-Change

Fundamentals

Return on Equity

―

Trailing 12-Months

Asset Growth

26.13%

Trailing 12-Months

This stock does not have enough of the key information we need to rate it accurately. Smart Score is calculated for stocks traded in Nasdaq, NYSE, TSE and LSE with a market cap above $30M and average 3 months trading volume above $30K.

Learn more about TipRanks Smart Score

Go to Top Smart score Stocks >

Company Description

Proteome Sciences PLC

Proteome Sciences PLC is protein biomarker research and development. The company uses high sensitivity proprietary techniques to detect and characterize differentially expressed proteins in diseases for diagnostic, prognostic and therapeutic applications. Its only reportable segment is the sale of goods and biomarker services. It generates maximum revenue from the TMT product. Geographically, it has a presence in the United States, the United Kingdom, and the European Union.

---